Notícias e Atividades da Endeavor BioMedicines

Veja o organograma con seus 16 executivos principais

Biografias mais buscadas da Endeavor BioMedicines

• John Hood, Chief Executive Officer and Director
• Andrew Lam, Director
• Bernard Davitian, Director

Criar um alerta
para seguir os movimentos de executivos da Endeavor BioMedicines.

Endeavor BioMedicines possui 2.405 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Vertex Pharmaceuticals (Estados Unidos).

Popular M&A news in Biotecnologia

• Ona Therapeutics acaba de anunciar uma arrecadação de fundos de 87 milhões de dólares. (publicado em 5 de junho de 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Oak Hill Bio acaba de anunciar uma arrecadação de fundos de 33 milhões de dólares. (publicado em 4 de junho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Carl Gordon - Director da Odyssey Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Endeavor BioMedicines

• Media Coverage | Endeavor BioMedicines
• Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer | Endeavor Biomedicines
• Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis | Endeavor Biomedicines
• Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors | Endeavor Biomedicines
• Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer | Endeavor Biomedicines
• Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) | Endeavor Biomedicines
• Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
• Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline | Endeavor Biomedicines
• Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | Endeavor Biomedicines
• Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib) | Endeavor Biomedicines
• View more press releases Close

Redes sociais sobre Endeavor BioMedicines

• Endeavor BioMedicines na Wikipedia, Google News e Yahoo Finance
• Endeavor BioMedicines na LinkedIn, X (Twitter) e YouTube